The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy

Hua Wang1,3, Xiaowen Zhou1,3, Chenbei Li1,2, Shuxiang Yan3, Chengyao Feng1,2, Jieyu He4, Zhihong Li1,2* and Chao Tu1,2*

Abstract
Pediatric cancers are the driving cause of death for children and adolescents. Due to safety requirements and considerations, treatment strategies and drugs for pediatric cancers have been so far scarcely studied. It is well known that tumor cells tend to progressively evade cell death pathways, which is known as apoptosis resistance, one of the hallmarks of cancer, dominating tumor drug resistance. Recently, treatments targeting nonapoptotic cell death have drawn great attention. Pyroptosis, a newly specialized form of cell death, acts as a critical physiological regulator in inflammatory reaction, cell development, tissue homeostasis and stress response. The action in different forms of pyroptosis is of great significance in the therapy of pediatric cancers. Pyroptosis could be induced and consequently modulate tumorigenesis, progression, and metastasis if treated with local or systemic therapies. However, excessive or uncontrolled cell death might lead to tissue damage, acute inflammation, or even cytokine release syndrome, which facilitates tumor progression or recurrence. Herein, we aimed to describe the molecular mechanisms of pyroptosis, to highlight and discuss the challenges and opportunities for activating pyroptosis pathways through various oncologic therapies in multiple pediatric neoplasms, including osteosarcoma, neuroblastoma, leukemia, lymphoma, and brain tumors.

Keywords: Pyroptosis, Programmed cell death, Pediatric cancer, Osteosarcoma, Cytokine release syndrome

Introduction
Cell death is a fundamental physiological process to maintain homeostasis, while it is also an abnormal pathological response to harmful stimuli. Traditionally, the concept of cell death is based on the morphology of dying cells, in equal to apoptotic cell death and necrotic cell death for a long time, which is also known as apoptosis and necrosis, respectively [1]. However, decades later, various kinds of cell death have sprung up, such as autophagy [2–4], pyroptosis [5, 6], PANoptosis [7, 8], necroptosis [9], ferroptosis [10, 11], cuproptosis [12, 13], parthanatos [14, 15], and alkaliptosis [16, 17] (Fig. 1). The expansion on morphological and biochemical features has enriched the definition of cell death. Pyroptosis is a gasdermin-mediated programmed cell death (PCD), which is closely related to inflammatory reaction [18]. Similar to apoptosis, it is also a kind of caspase-driven PCD but triggered by inflammasomes [19]. Additionally, the process inducing cell rupture and the release of cellular contents is consistent with necrosis to some extent [20].

Currently, pediatric cancers are still the driving causes of death for children and adolescents [21–23]. However, the underlying pathogenesis of most pediatric neoplasms remains largely unelucidated [24]. Due to the safety requirements and considerations for therapies in pediatric cancers, treatment strategies and drugs are far too scarce [25]. According to FDA database, only around 40% of children with cancer living...
in most developing countries tend to survive five years after initial diagnosis. Meanwhile, only eleven drugs have been approved for anticancer therapy in under-age from 1980 to 2017 [26, 27]. Therefore, there is an urgent need in pediatric cancers.

Tumor cells tend to progressively evade the cell death pathways, which exert as protective mechanisms to remove damaged cells [28]. Classical forms of cell death, including apoptosis and necrosis, are important anticancer defense mechanisms in tumor killing, which have been extensively explored [1, 29]. Recently, mounting evidences have shown that pyroptotic inflamasomes and the relevant cytokines can affect tumorigenesis such as metastasis, proliferation, and invasion [30–32]. Related pathways and targets have shed light on the potential role of pyroptosis in cancer therapeutics among virous pediatric cancers like osteosarcoma [33–36], neuroblastoma [37–39], etc. However, uncertainties in treatment efficacy and the pyroptosis-mediated adverse effects reveal that the relationship between pyroptosis and pediatric cancers is not fully understood at present. Hence, we aim to focus on the molecular mechanisms, the virous functions and potential clinical applications or challenges of pyroptosis in multiple pediatric malignancies. In addition, we summarized a number of findings in order to raise awareness of pediatric cancers and identify dozens of potential cancer treatment candidates as well.

**Overview of pyroptosis**

**Pyroptosis and cell death**

Cell death is a common phenomenon in prokaryotic and eukaryotic cells. With the persistent progression in the field, novel signal transduction modules and inventive detection of the pathophysiological relevance have updated the classification of cell death. As the research hotspot, pyroptosis is a type of PCD that critically depends on the formation of plasma membrane pores by members of the gasdermin protein family. It is known that pyroptosis can induce inflammation with stimuli of toxins, chemotherapy drugs, and bacterial, and viral pathogens [40–43]. Termed as "pyroptosis", it is composed of two parts originated from the Greek roots “pyro” and “ptosis”, which means “fire” and “falling”, respectively [44]. The most characteristic part of pyroptosis is the inflammatory reaction when compared with other forms of cell death. Generally, cleavage of gasdermin, leakage of interleukin (IL-1β/IL-18), bubble-like protrusions on cell membrane are typical cellular morphological features of pyroptosis, thus forming pores in the plasma membrane and allowing water to flow into the cells, and consequently causing cell swelling and lysis [45]. This process is diverse from necrosis with an explosive rupture of the plasma membrane. In contrast to fragmented nucleus in apoptosis, nuclear integrity is maintained in pyroptosis [46, 47]. DNA fragmentation is the same characteristic of pyroptosis and apoptosis, but ordered in apoptosis while random in pyroptosis [46, 48].
The modality of cell death can be divided into two categories, namely the accidental cell death (ACD) and regulated cell death (RCD), according to the speed at which cell death occurs and its potential control by drugs or genes [1, 49]. In general, PCD is completely physiological forms of RCD. As a novel form of PCD, the morphological changes of pyroptosis are distinctive from other classical forms of cell death. However, pyroptosis still holds some features that are consistent with apoptosis or necrosis, just like a mixture of the two to some extent [50, 51]. Similar to pyroptosis, necroptosis is also a lytic and inflammatory type of PCD that requires the membrane damaging proteins, but in a caspase-independent fashion mainly mediated by receptor-interacting protein 1 (RIP1), RIP3, and mixed lineage kinase domain-like (MLKL) [20, 52] (Fig. 2). Notably, due to the extensive cross talk among pyroptosis, apoptosis and necroptosis, the concept of PANoptosis is established. PANoptosis is an inflammatory PCD pathway with key features of pyroptosis, apoptosis, and/or necroptosis, although differences exist in key initiators, effectors, and executioners in each of these three PCD pathways [7, 53–55]. Ferroptosis is classified as regulated necrosis that is characterized by iron-dependent lipid peroxidation and contains various biologic processes like lipid metabolism, iron metabolism, oxidative stress, and biosynthesis of nicotinamide adenine dinucleotide phosphate (NADPH), glutathione (GSH), and coenzyme Q10 (CoQ10) [56–58]. More recently, excess concentration of copper is currently conformed to mediate a distinct form of cell death, which is dependent on mitochondrial respiration and protein aggregation [12, 59]. Pyroptosis is an inflammatory form of PCD, while autophagy is a subcellular process that plays an important role in maintaining homeostasis when degradation of proteins and damaged organelles occur [60, 61]. Taken together, the comparisons of the characteristics among these different forms of PCD are briefly summarized in Table 1.

Molecular mechanisms of pyroptosis

The formation of extracellular or intracellular stimulation and inflammasome is the initial process of pyroptosis [74, 75]. Afterward, various inflammasomes act as platforms for the activation of caspases, which subsequently starts or executes cellular programs [1, 76]. Triggered by different caspases, the pathways associated with pyroptosis can be generally divided into canonical pathway, noncanonical pathway and other pathways, including caspase-3/8-mediated pathway and granzyme-mediated pathway [77]. The detailed pyroptotic pathways are depicted as follows:

**Canonical pyroptotic pathway**

Canonical pyroptosis is mediated by caspase-1, with inflammasome assembly, gasdermin D (GSDMD) cleavage and interleukin release (mainly IL-1𝛽 and IL-18) [18, 20, 78]. Pattern recognition receptors (PRRs) like Toll-like receptors (TLRs) and nod-like receptors (NLRs) recognize intracellular and extracellular signals, mainly danger-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs), then initiate a signaling cascade which leads to pro-inflammatory cytokines release and GSDMD-mediated cell death [79, 80]. The canonical inflammasome can be assembled by inflammasome sensors like nod-like receptor protein 1 (NLRP1), NLRP3, NLR family CARD domain-containing protein 4 (NLRC4), AIM2, and pyrin [77], thus detecting diverse microbial or intracellular danger signals and activating caspase-1 [29].

At the beginning, expressions of inflammasome components, including NLRP3, caspase-1 and pro-IL-1𝛽, are increased with an up-regulation of nuclear factor-kB (NF-kB) [81, 82]. Then, inflammasome sensors like NLRP3 are activated via stimulation of various pathogenic signals induced by numerous PAMPs or DAMPs like lysosomal disruption [83], K+ efflux [84], Ca2+ flux [85], etc. The inflammasome sensors assemble with pro-caspase-1 and apoptosis-related speck-like protein (ASC) afterward, to form inflammasomes and activate caspase-1. Activated caspase-1 cleaves GSDMD into N-terminal domain of GSDMD (GSDMD-N), which leads to nonselective pores forming on cell membrane, and eventually results in cell swelling and lysis. It also induces the conversion of pro-IL-18 and pro-IL-1𝛽 into mature inflammatory cytokines, hence further promoting the transcriptional activities of NF-kB and numerous factors in other inflammatory and stress-induced pathways [82, 86] and thereby forming a positive feedback loop (Fig. 3).

**Noncanonical pyroptotic pathway**

Noncanonical pyroptotic pathway is simpler and more straightforward compared with the former, which is triggered by the activation of caspase-4/5 in human and caspase-11 in mice, respectively [76, 77]. Noncanonical inflammasome sensors can directly detect intracellular bacteria and lipopolysaccharide (LPS), thus activating caspase-4/5/11. Later, with a process of GSDMD cleavage, cell membrane pores formation, and osmotic cell lysis, pyroptosis is forming. It is worth noting that ion influx and efflux play a significant role in this process. Cleavage of GSDMD results in efflux of K+ [18, 87], which can not only lead to unbalanced osmotic pressure and water influx, but can also help mediate the assembly of NLRP3 inflammasome [86, 88, 89], thus
promoting pyroptosis. Intriguingly, caspase-4/5/11 can only mediate the maturation and secretion of IL-1β/IL-18 in canonical caspase-1 pathway without directly cleaving them [29]. Additionally, caspase-11 is conformed to cleave pannexin-1 followed by cellular adenosine triphosphate (ATP) release, purinergic P2X7 pathway activation, and eventually lead to cytotoxicity or cytolysis [90], which is a significant supplement to noncanonical pyroptotic pathway (Fig. 3).
Table 1  Comparison of known programmed cell death

| Type           | Cellular morphological features | Biochemical features | Immune features |
|----------------|---------------------------------|----------------------|-----------------|
|                | Morphology Membrane Organelle   | DNA Pore-forming cause | Caspase-dependent | Inflammation | Remark(s) |
| Pyroptosis     | Swell Pore formation Intact/deformed | Inflammasome          | RD Gasdermin protein | √ √         | √         | ICD       |
| Apoptosis      | Shrink Intact                   | Apoptotic body       | LD No            | × √         | ×         | TCD or ICD |
| Necroptosis    | Swell Pore formation Swell      | Necrosis ²            | RD MLKL          | √ ×         | √         | ICD       |
| Autophagy      | Crescent-shaped Swell Pore formation Smaller mitochondria | Autophagosome | RD No            | × ×         | ×         | ICD       |
| Ferroptosis    | Swell Pore formation Smaller mitochondria | Autophagosome | RD Iron-dependent lipid peroxidation | √ ×         | √         | ICD       |
| PANoptosis     | NA Pore formation NA            | PANoptosome           | RD Gasdermin/MLKL | √ √         | √         | TCD or ICD |
| Parthanatos    | Not swell Loss integrity NA     | Chromatin condensation | Large DNA fragmentation | NA x         | √         | ICD       |
| Alkaliptosis   | Necrosis-like Pore formation swell | Alkalization-dependent | NA NA | NA x         | √         | ICD       |

* √ indicates “IL-1B, IL-1B release”; # indicates “a key molecular signaling platform in necroptosis primarily comprising RIPK1 and RIPK3”; ICD: immunogenic cell death; IL: interleukin; LD: ladder degradation; MLKL: mixed lineage kinase domain-like; NA: not available; RD: random degradation; RIP: receptor-interacting protein; TCD: tolerogenic cell death
Other pathways
At present, caspase-3/8-mediated pathway and granzyme-mediated pathway have been reported (Fig. 4). The former one is triggered by caspase-3/8, which is previously considered as the exclusive process in apoptosis. The view was expanded with the discovery of caspase-3-mediated gasdermin E (GSDME) cleavage in tumor cells induced by chemotherapeutic drugs [62], and caspase-8-related cleavage of GSDMD in mouse macrophages during Yersinia infection [91]. Interestingly, tumor necrosis factor (TNF)-mediated apoptosis is converted into pyroptosis with the expression of gasdermin C (GSDMC) mediated by programmed cell death ligand 1 (PD-L1) in breast cancer [92]. Under hypoxia conditions, PD-L1 is transferred to the nucleus and with the help of p-Stat3, and they together upregulate the expression of GSDMC. Later, caspase-8 specifically cleaves GSDMC and eventually induces pyroptosis [92, 93]. Additionally, chemo-antibiotic drugs like daunorubicin, actinomycin D, doxorubicin (DOX), and epirubicin were found to increase the expression of GSDMC and nuclear PD-L1 in breast cancer, which further promoted caspase-3/8-mediated pathway and ultimately led to pyroptosis [92, 93].

Granzyme-mediated pathway further broadens the definition of pyroptosis, which was previously known to be only activated by caspases [94, 95]. Studies found that chimeric antigen receptor-T (CAR-T) cells could activate caspase-3 in target cells and release granzyme B (GzmB), subsequently causing GSDME-mediated pyroptosis, while granzyme A (GzmA) secreted from
CD8+ T cells and NK cells could induce gasdermin B (GSDMB)-mediated pyroptosis [95, 96].

**Pyroptosis in common pediatric cancers**

Here, we discussed the recent advances concerning the underlying molecular mechanisms of pyroptosis and the potential challenges for regulating pyroptosis pathways through various oncologic therapies in several common pediatric cancers, including osteosarcoma, neuroblastoma, leukemia, lymphoma, and brain tumors. The detailed findings are shown in Table 2 and Fig. 5.

**Osteosarcoma and pyroptosis**

Osteosarcoma, a kind of malignant tumor derived from mesenchymal tissue, is highly aggressive in young populations [97, 98]. The incidence of osteosarcoma is bimodal with age, with an initial peak at 10–14 years of age, and a second peak after 60 years [99]. Primarily, osteosarcoma tends to occur in the metaphysis of the distal femur and proximal tibia [100], while metastasis is mainly detected in the lung [101, 102]. With an annual incidence of approximately 3–4 patients per million, osteosarcoma is a relatively common malignant tumor in pediatric cancers, as well as one of the leading causes of cancer-related death in children and adolescents [103, 104]. Owing to...
the combination of surgical resection and neoadjuvant chemotherapy, osteosarcoma is among the most curable malignant tumors of high-grade sarcomas and achieves a long-term survival rate about 70% in patients with localized disease [105, 106]. However, patients still suffer from unsatisfactory clinical outcomes including physical disability, drug resistance and other serious adverse effects [107, 108], especially in patients with pulmonary metastasis or local relapse. This also reflects the slow progress of osteosarcoma treatment paradigms, treatment satisfaction and survival rate over the past few years. Therefore, the identification of novel therapeutic agents and treatment strategies is urgently needed.

Recently, emerging researches have focused on different targets in the pyroptosis pathways and investigated the regulatory role and molecular mechanisms of pyroptosis among different models, which have brought mounting promising candidates for the osteosarcoma treatment. Inspired by traditional Chinese medicine, Ding et al. found that dioscin (a steroidal saponin derived from medicinal plants) inhibited the growth of human osteosarcoma both in vitro and in vivo [33], demonstrating the anticancer potential of dioscin in osteosarcoma. Dioscin could inhibit osteosarcoma cell proliferation and induce G2/M-phase arrest and apoptosis in a concentration-dependent manner. Compared with the control, shrinkage, chromatin condensation, and nuclear fragmentation were more frequently observed in osteosarcoma cells exposed to dioscin. Additionally, involvement of caspase-3-GSDME pore on the cancer cell membrane [33]. Besides, one GSDMD-targeted statistical analysis

| Cancer types       | Design                     | Experimental design | Cellular process                                                                 | Cell viability and impact                                      |
|--------------------|----------------------------|---------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------|
| Osteosarcoma       | Dioscin                    | In vitro/in vivo    | G2/M-phase arrest, apoptosis, and GSDME-dependent pyroptosis                      | Inhibited cell proliferation                                   |
|                    | Clinical control and statistical analysis | Primary clinical samples and normal bone tissues | NA                                                                               | Poor chemotherapy response, distant metastasis, worse prognosis |
| Neuroblastoma      | Dasatinib                  | In vitro            | Pyroptosis                                                                        | Low cell survival rate                                          |
|                    | CPF                        | In vitro            | NLRP3-dependent pyroptosis via miR-181/SIRT1/PGC-1α/Nrf2 pathway                    | Inhibited cell viability, and proliferation                    |
|                    | BM-MSCs-Exo                | In vitro            | OGD-mediated pyroptosis, inhibited GSDMD shuttle from nucleus to cytoplasm        | Reduced dead cell ratio                                         |
| Leukemia           | Val-boroPro                | In vitro/in vivo    | Pro-caspase-1-dependent pyroptosis                                               | Reduced cell viability, and increased cell death ratio          |
|                    | MgSO4                      | In vitro            | Inhibited ASC oligomerization, NLRP3-dependent pyroptosis                          | Smaller cell size, lower level of pyroptotic cell death         |
|                    | Tp92                       | In vitro            | Atypical pyroptosis via pro-caspase-1 pathway, apoptosis via the RIPK1/caspase-8/caspase-3 pathway | Increased cell death ratio                                     |
|                    | CAR-T cells incubated with CD19-i-leukemic cells | In vitro/in vivo | GSDME-mediated pyroptosis                                                         | Decreased cell viability, CRS controlled                        |
| Lymphoma           | Sesamin                    | In vivo             | Apoptosis, pyroptosis, autophagy                                                 | Inhibited growth and proliferation                               |
|                    | BAFF                       | In vitro            | NLRP3-dependent pyroptosis, src activity-dependent ROS production, potassium ion efflux | Decreased cell viability                                        |
|                    | OX40 stimulation           | In vivo             | Pro-caspase-1-dependent pyroptosis                                               | Decreased cell viability, and liver injury                      |
|                    | Iridium (III) complexes    | In vitro*           | Mitochondria-mediated apoptosis, GSDME-mediated pyroptosis                        | Decreased cell viability                                        |
| Brain tumors       | Benzimidazoles             | In vitro/in vivo    | Cell cycle arrest via P53/P21/cyclin B1, mitochondria-dependent apoptosis, NLRP3-dependent pyroptosis | Inhibited cell proliferation, migration, and invasion           |
|                    | Galangin                   | In vitro/in vivo    | Apoptosis, pyroptosis and autophagy                                              | Suppressed tumor growth, reduced cell viability and proliferation |
|                    | miRNA-214                  | In vitro            | Caspase-1-mediated pyroptosis                                                     | Inhibited cell proliferation and migration                      |

*indicates lung carcinoma, gastric adenocarcinoma, hepatocellular carcinoma, cervical cancer, and melanoma; AML: acute myeloid leukemia; CPF: chlorpyrifos; CRS: cytokine release syndrome; GSDMD: gasdermin D; GSDMD-N: gasdermin D N-terminal; GSDME: gasdermin E; GSDME-N: gasdermin E N-terminal; HMGB1: high-mobility group protein box 1; IL: interleukin; MDS: myelodysplastic syndromes; NA: not available; NLRP3: nod-like receptor protein 3; OGD: oxygen–glucose deprivation; PTX: paclitaxel; ROS: reactive oxygen species
showed the GSDMD was significantly overexpressed in osteosarcoma compared to non-neoplastic counterparts, and the elevated expression of GSDMD was obviously associated with poor chemotherapy response, distant metastasis, and worse prognosis of osteosarcoma patients [34]. It is known that pyroptosis may result in the cleavage of GSDMD and activation of cytokines such as IL-1β and IL-18 [1]. It is estimated that upregulated GSDMD expression might play a considerable role in the progression and treatment resistance of osteosarcoma, which was already observed in other carcinomas, including nonsmall cell lung cancer [109], bladder cancer [110], and breast cancer [111].

Currently, there are few in vitro or in vivo studies concerning the role of pyroptosis in osteosarcoma, but the related prognostic analysis may also have some implications in evaluation of both treatment and prognosis. Zhang et al. identified a novel pyroptosis-related gene signature to predict the prognosis and indicate the features of immune microenvironment of patients with osteosarcoma [36]. Six pyroptosis-associated risk genes were identified via univariate and LASSO regression analysis. Combined with other clinical characteristics, an independent pyroptosis-related prognostic factor named "PRS-score" for osteosarcoma patients was established, which might be an important contribution to early diagnosis and prognosis of immunotherapy in osteosarcoma [36]. Similarly, another study constructed three differentially expressed pyroptosis-related long noncoding RNA (lncRNA) signature linked to osteosarcoma microenvironment and prognosis [35], which had critical predictive value for the prognosis of osteosarcoma patients and may be promising targets for future therapy.

**Neuroblastoma and pyroptosis**

Neuroblastoma, mainly affecting the normal development of the paravertebral sympathetic ganglia and adrenal medulla, is the most common extracranial embryonal malignancy in children [112]. Different locations of the tumor and paraneoplastic syndromes contribute to variable manifestations of neuroblastoma, leading to dramatic prognosis ranging from spontaneous tumor regression to widespread metastasis, which is unresponsive to treatment [113, 114]. Children at high risk of neuroblastoma metastasis or mortality receive multimodality treatment, but may suffer from complications like nausea and pain. MYCN gene amplification has been confirmed to be in line with high-risk cases of neuroblastoma [112]. Tremendous efforts to develop MYCN inhibitors with desirable outcomes indicate that this nuclear transcription factor may be difficult to target therapeutically. Aiming at better cures and long-term quality of life for children with cancer, identification of novel immunotherapy agents and tumor targets are underway with several promising
approaches like \textsuperscript{123}I-MIBG imaging followed by autologous stem cell rescue [115], lutetium 177-DOTATATE [116], and activating mutations in the genes of RAS-MAPK pathway [117], etc. However, breakthrough is still far from reach.

Recent advances in pyroptosis research have cast a light in the dark. Gasdermins are typical proteins involved in pyroptosis, and their cleavage fragments can insert into the cell membrane and thus play different roles in cytokysis. GSDME, participating in chemotherapy-induced pyroptosis in tumor cells, is promoted by anti-oncogene p53 [62, 118]. But continuous expression of p53 leads to apoptosis in normal cells after treatment with cytotoxic anti-tumor agents [119]. Zhang and colleagues reported that dasatinib could induce pyroptosis in neuroblastoma SH-SY5Y cells and increase the protein levels of GSDMD and GSDME out of the effect of p53 [38]. It is of significant importance in therapy efficacy of neuroblastoma. Pyroptosis caused by small molecule toxicants has been reported in several studies like athiopyran derivative with low murine toxicity [120], and bilirubin mediated toxicity in cultured rat cortical astrocytes [121], etc. Interestingly, one study showed that the level of pyroptosis-related proteins was significantly increased in a dose and time-dependent manner in SH-SY5Y cells when treated with insecticide chlorpyrifos (CPF) [39]. By upregulating miR-181 through downregulation of the SIRT1/PGC-1α/Nrf2 pathway, CPF promotes cell pyroptosis, inhibits cell proliferation and increases susceptibility to oxidative stress-induced toxicity. But the active ingredients and toxicity of CPF should be considered in therapeutic treatment.

In addition of anti-tumor effect, the role of pyroptosis on noncancerous tissue damage has been investigated as well. For example, Kang et al. reported the neuroprotective effects of bone marrow mesenchymal stromal cells-derived exosomes (BM-MSCs-Exo) under normoxic and hypoxic conditions, which named N-BM-MSCs-Exo and H-BM-MSCs-Exo, respectively. The research was investigated on oxygen–glucose deprivation (OGD) injury in mouse neuroblastoma N2a cells and rat primary cortical neurons [37]. Functional assays and mechanistical analysis showed that pyroptosis-related proteins were decreased in both groups, demonstrating that hypoxic BM-MSCs-Exo may have a more pronounced protective effect in ameliorating the progression of cerebral ischemia and hypoxia injury in patients.

Leukemia and pyroptosis

Leukemia is a common pediatric cancer characterized by abnormal excessive proliferation of hematopoietic stem cells in bone marrow or blood [122, 123]. It can be mainly divided into two categories: acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML), among which ALL is more prevalent [124, 125]. As a novel inflammasome sensor, caspase recruitment domain-containing protein 8 (CARD8) can bind to procaspase-1 [126, 127], and it was confirmed to trigger pyroptosis in myeloid leukemia cells through inhibition of dipeptidyl peptidases (DPP) [128]. Nonselective DPP-inhibitor val-boroPro (also called PT-100 and talabostat) is a common anticancer drug, which can inhibit DPP8/9, thus inducing pyroptosis in a NLRP1b-dependent manner in myeloid cells [127]. Further studies showed that val-boroPro could induce pyroptosis in multiple kinds of AML cell lines in vitro, and inhibit the AML progression in vivo. Taken together, inhibition of DPP may be a novel therapeutic strategy for AML [127, 129]. It is known that calcium signaling is important in the activation of the NLRP3 inflammasome [130, 131]. As a common calcium antagonist, MgSO4 could inhibit the release of calcium-influx-dependent histamine [132], which enables its potential anti-inflammatory effect. Based on this, Chang et al. found that MgSO4 could downregulate NLRP3 inflammasome, caspase-1 and IL-1β in THP-1 cells (human monocytic cell line derived from an acute monocytic leukemia patient), thus inhibiting NLRP3-dependent pyroptosis [133]. Additionally, another study proved that Tp92, the only outer membrane protein of Treponema pallidum [134] could induce human mononuclear cell death and IL-8 secretion. And interestingly, among the various mechanism, Tp92 may induce atypical pyroptosis of THP-1 cells via the pro-caspase-1 pathway [135]. However, it is worth noting that the production of IL-1β and IL-18 is absent in this process, which is commonly seen in canonical pathway of pyroptosis. As a result, CAR-T cell therapy is a great success in clinical applications of genetically engineered T cells modified with CARs against B cell malignancies, but cytokine release syndrome (CRS) significantly restricts its effectiveness and extensibility [136, 137]. A study by Liu et al. reported that upon incubation with CD19+ leukaemic cells, CAR-T cells could increase the release of lactate dehydrogenase (LDH), and upregulate expression GSDME and IL-1β, suggesting that CAR-T cells can activate GSDME-mediated pyroptosis by releasing a large amount of perforin and GzmB, and could ultimately result in CRS [94]. Further study also revealed that CRS occurrence significantly decreased when depleting macrophages, knocking out GSDME, or inhibiting caspase-1 in mouse models [94]. Since high expression of GSDME is observed in B leukemic cells, the induction of CRS may impede the application of pyroptosis related CAR-T therapy in leukemia. Therefore, studies focusing on other forms of PCD may be alternative promising choices for CAR-T therapy.
Lymphoma and pyroptosis
Lymphoma is a common but highly treatable malignancy in children [138]. It can be further divided into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) [139]. Accounting for about 5% of childhood cancers, NHL is more likely to occur in younger children when compared with HL. However, NHL is still uncommon in children younger than 3-year-old [140]. NHL may develop from either abnormal B or T cells, while HL derives from a specific abnormal B lymphocyte lineage [141].

Sesamin is a plant-derived compounds with many pharmacological effects including antiproliferative, antimetastatic, anti-inflammatory, and proapoptotic functions [69, 142, 143], which makes it a promising candidate for anticancer treatment. It is reported that sesamin markedly inhibited growth and proliferation of EL4 cells by inducing apoptosis, pyroptosis and autophagy to strengthen the anti-tumor effects on murine T cell lymphoma [144]. B cell-activating factor (BAFF), a member of TNF superfamily, supports B cell survival and homeostasis through the activation of the NF-κB pathway [145]. It is well known that NF-κB is a key initiating signal of NLRP3 inflammasome [146], but the relationship between BAFF and NLRP3 inflammasome remains unclear. Lim et al. firstly demonstrated BAFF induced the activation of NLRP3 inflammasomes with increased expression of NLRP3, IL-1β, and caspase-1, and ultimately leading to pyroptosis in primary B cells and B lymphoma cell lines [147]. Coincidentally, another TNF superfamily receptor OX40 (also called CD134) was found to trigger the activation of caspase-1, resulting in IL-1β expression as well as the cleavage of the pyroptotic protein GSDMD in invariant nature killer T (iNKT) cells [148]. Of note, iNKT cells mainly reside in liver, more researches on its three iridium (III) complexes [70]. When trapped in liposomes, these complexes can trigger mitochondria-mediated apoptosis and GSDME-mediated pyroptosis in a variety of cancers, including lung carcinoma, gastric adenocarcinoma, and melanoma. More work in progress identifying the effect of these complexes in lymphoma may help bring potential anticancer strategies about TFBIP in this malignancy in the future.

Brain tumors and pyroptosis
Primary tumors of central nervous system (CNS) are the most frequent solid tumors in children, contributing to about 15% to 20% of all malignancies in pediatrics [149]. Pediatric high-grade glioma (pHGG) is one of the rapidly lethal malignancies at young age [150, 151]. Among them, glioblastoma, also known as glioblastoma multiforme (GBM), is the most prevalent and aggressive [152]. To date, surgical resection followed by adjuvant radiation therapy and chemotherapy with oral temozolomide (TMZ) is the most common and effective treatment for GBM patients [153]. However, TMZ, the only drug available for GBM, frequently induces drug resistance and numerous side effects [154].

A study by Ren et al. found benzimidazoles can induce cell cycle arrest at the G2/M phase via the p53/p21/cyclin B1 pathway, and concurrently induce mitochondria-dependent apoptosis and NLRP3-dependent pyroptosis in glioblastoma cells [30]. Another study revealed a natural flavonoid Galangin could also elicit a potent anti-tumor effect on GBM by initiating apoptosis, pyroptosis and autophagy [67]. These novel drugs cater to the urgent clinical need for GBM therapeutics especially in patients who are resistant or less responsive to TMZ. MicroRNAs (miRNAs) are small endogenous noncoding RNAs with a variety of targets, and thus exerting diverse functions in tumorigenesis, progression, and metastasis [155–157]. In glioma, an inverse relationship between abundant caspase-1 expression and low expression of miRNA-214 was observed [158, 159]. Following this, another research further confirmed caspase-1 as a target gene of miRNA-214 by luciferase reporter assay [71]. Moreover, miRNA-214 was found to inhibit cellular proliferation and migration via caspase-1 dependent pyroptosis in glioma [71]. In addition to approved drugs repurposing and new drugs development, Lu et al. reported a novel strategy to package recombinant adeno-associated virus (rAAV) expressing GSDMD-N. They have successfully delivered GSDMD-N into tumor cells and demonstrated pyroptosis induced by these rAAVs in preclinical cancer models including glioblastoma [72], which can provide enlightenment for the idea of anti-tumor therapy. Till now, a growing body of research has posted attention on GBM. Exploration of novel drugs, and combination of traditional methods or medicine may also facilitate progression in pediatric brain tumors.

Pyroptosis related therapy in pediatric cancers
Apoptosis resistance is a general hallmark of cancer in the mechanism of tumor drug resistance [160, 161]. Recently, treatments that target nonapoptotic cell death have attracted great attention [162, 163]. Therefore, the research in different forms of pyroptosis is of great significance for the treatment therapy of pediatric cancers (Fig. 6).
Chemotherapy drug-induced pyroptosis

Chemotherapy is a diverse and rapidly progressing field [164, 165]. While most researches explicitly cast attention to adult diseases, considerable efforts are being made to bring these therapies into the pediatric cancers. Chemotherapy drugs can initiate caspase-3-mediated apoptosis in cancer cells, but the process will be switched to pyroptosis with abundant GSDME expression [62, 166]. As proved, GSDME is lowly expressed in most cancer cells [167–170], so we can suppose that with reversal of GSDME expression level, pyroptotic therapy may exert an important role in cancer treatment.

Decitabine and azacitidine are classical drugs to treat myelodysplastic syndromes (MDS) or AML [171, 172]. It is reported that these drugs can increase GSDME expression and sensitize the cancer cells to chemotherapy drug by inducing GSDME-mediated pyroptosis [62, 63]. Additionally, dasatinib, a multi-kinase inhibitor, can induce pyroptosis in GSDME-expressing lung cancer and neuroblastoma, and increase the expression of GSDMD and GSDME in a p53-independent manner [38]. Paclitaxel (PTX) and cisplatin are representative chemo-drugs for lung cancers by inducing apoptosis, and are lately found to induce GSDME-dependent pyroptosis as well [64]. Of note, compared with PTX, cisplatin induces more severe secondary pyroptosis with higher expression of GSDME-N in lung cancer, indicating cisplatin may be a better candidate for lung cancers in pyroptosis-related therapy [64]. Wang et al. and colleagues further expanded the choices of chemotherapy drugs to DOX, actinomycin-D, bleomycin and topotecan for pyroptotic treatment in lung cancer [62]. Besides, Yu et al. found that lobaplatin could induce GSDME-dependent pyroptosis in colon cancer via reactive oxygen species (ROS) elevation, c-Jun N-terminal kinase (JNK) activation and initiation of the mitochondrial apoptotic pathway [65]. As a negative regulator of protein synthesis, eukaryotic elongation factor-2 kinase (eEF-2 K) is observed highly expressed in various tumor cells and proved to exert a critical function in modulating autophagy and apoptosis in tumor cells [173, 174]. Practically, lung cancer, colon cancer, and melanoma are uncommon in children. Current mainstream researches post their focus on adult diseases,
but in fact, relevant novel research results and methods may also be applicable to clinical practice.

Intriguingly, therapies that inhibit pyroptosis via gasdermins may also effectively modulate tumor progression as well. A recent study established a novel targeted nanomedicine by packaging specific anti-GSDMB antibody into HER2 breast cancer cells and investigated its anti-tumor effect both in vivo and in vitro. The results showed that the therapy could effectively inhibit tumor growth and cell migration, suppress tumor resistance, and diminish lung metastasis [175]. More studies concerning pyroptosis-related therapy in malignancies are demanded to further address this controversial issue.

**Nonchemotherapy drugs-induced pyroptosis**

Chemotherapeutic drugs are commonly used to maintain the patients’ condition, but adverse effects like weight loss, listlessness, and tissue damage may always occur after long-term or overdose treatment [176]. Natural products and other therapies have turned into inviting alternatives in clinical practice for its low toxicity, wide source, and human affinity [177, 178]. As aforementioned, dioscin can inhibit cell proliferation in human osteosarcoma both in vitro and in vivo via GSDME-dependent pyroptosis [33]. As a member of natural flavonoids, galangin exerts a vital role in suppressing tumor growth and reducing cell viability of glioblastoma cells by triggering GSDME-dependent pyroptosis [67], while anthocyanin promotes the cell death of oral squamous cell carcinoma (OSCC) via activation of GSDMD-dependent pyroptosis [68]. Additionally, sesamin, a widely used plant-derived compound with multi-anti-tumor pharmacological effects, can inhibit the growth and proliferation of murine T cell lymphoma in vivo by regulating apoptosis and pyroptosis [69].

Interestingly, composite or synthetic agents can also be effective in anti-tumor treatment via pyroptotic pathway [179]. A new synthesized ligand TFBIP and its three iridium (III) complexes were found to induce GSDME-mediated pyroptosis, thus decreasing cell viability in several cancers [70]. MiR-214 targeting caspase-1 or GSDMD-N packaged in rAAVs can both induce pyroptosis in brain tumor cells [71, 72]. The reagent consisting of BRAF inhibitors and MEK inhibitors (BRAFi/MEKi) is used to treat BRAFV600E/K-mutant melanoma with FDA approval. Further studies found that BRAFi/MEKi can induce pyroptosis with cleavage of GSDME and release of proinflammation factors like high mobility group protein B1 (HMGB1, an inflammatory marker of pyroptosis) [73]. Collectively, the mechanisms of these compound-based therapies are concluded in Table 3 for a better understanding.

**Radiotherapy-induced pyroptosis**

Radiotherapy is a common clinical treatment for local malignancies, which can release tumor antigens as an endogenous tumor vaccination event to further induce tumor infiltration of CD8+ T cells, and ultimately leads to the shrinkage of primary tumor and distal metastases [180, 181]. Radiotherapy itself can not only trigger

---

**Table 3** Compounds inducing pyroptosis signal pathways in cancers

| Classification     | Compounds                  | Cancer types                          | Mechanisms of pyroptosis induction            | References |
|--------------------|----------------------------|---------------------------------------|-----------------------------------------------|------------|
| Chemotherapy drugs | Decitabine/azacitidine     | MDS/AML                               | Caspase-3/GSDME                               | [62, 63]   |
|                    | Dasatinib                  | Neuroblastoma/Lung cancer             | Caspase-3/GSDME                               | [38]       |
|                    | PTX/cisplatin              | Lung cancer                           | Caspase-3/GSDME                               | [64]       |
|                    | DOX, Actinomycin-D, Bleomycin, Topotecan | Lung cancer                           | Caspase-3/GSDME                               | [62]       |
|                    | Lobaplatin                 | Colon cancer                          | ROS/JNK/caspase-3/GSDME                       | [65]       |
|                    | DOX                        | Melanoma                              | eEF-2K/caspase-3/GSDME                        | [66]       |
| Natural products   | Dioscin                    | Osteosarcoma                          | Caspase-3/GSDME                               | [33]       |
|                    | Galangin                   | Brain tumors                          | GSDME                                         | [67]       |
|                    | Anthocyanin                | OSCC                                  | NLRP3/caspase-1/GSDMD                         | [68]       |
|                    | Sesamin                    | Lymphoma                              | NLRP3/caspase-1                               | [69]       |
| Reagents           | Iridium (III) complexes    | Several cancers*                      | Caspase-3/GSDME                               | [70]       |
|                    | miRNA-214                  | Brain tumors                          | Caspase-1                                     | [71]       |
|                    | GSDMD-N packaged in rAAVs  | Brain tumors                          | GSDMD                                         | [72]       |
|                    | BRAFi/MEKi                 | Melanoma                              | GSDME/HMGB1                                  | [73]       |

*indicates lung carcinoma, gastric adenocarcinoma, hepatocellular carcinoma, cervical cancer, and melanoma; AML: acute myeloid leukemia; BRAFi: BRAF inhibitor; DOX: doxorubicin; eEF-2K: eukaryotic elongation factor 2 kinase; GSDMD: gasdermin D; GSDME: gasdermin E; HMGB1: high mobility group protein box 1; JNK: c-Jun N-terminal kinase; MDS: myelodysplastic syndromes; MEKi: MEK inhibitor; NLRP3: nod-like receptor protein 3; OSCC: oral squamous cell carcinoma; PTX: paclitaxel; ROS: reactive oxygen species
immunogenic cell death (ICD) in tumor cells, but can also assist chemotherapy-induced ICD with a combination of other treatment [181, 182]. The ideal radiotherapy should eliminate as many tumor cells as possible without damaging the normal tissues and inducing inflammation. Combination of radiotherapy with other therapies have been well applied in clinical trials for treatments of various cancers, including head and neck cancer [183], ovarian cancer [184], and nonsmall cell lung cancer [185]. Currently, few studies accurately describe the relationship between pyroptosis and radiotherapy. As aforementioned, AIM2 is a classical inflammasome sensor involved in canonical pyroptosis pathway. Hu et al. found that AIM2 was sensitive to double-strand DNA break in the nucleus caused by ionizing radiation and chemotherapeutic agents, thus inducing inflammasome activation and subsequent pyroptosis [186]. Another study by Li et al., also demonstrated high-dose X-ray irradiation could trigger pyroptosis that modulated by connexin 43 (Cx43) in the human umbilical vein endothelial cells (HUVECs) [187], implicating a vital correlation between radiotherapy and pyroptosis.

However, it is noteworthy that a few studies have clearly shown that radiation can cause radiotherapy-related toxicity upon activation of pyroptosis, such as bone marrow inhibition and gastrointestinal tract injury [180, 186, 188]. For instance, Liu et al. reported that radiation could induce NLRP3-mediated pyroptosis in primary cultured bone marrow-derived macrophages both in vitro and in vivo [189], suggesting that targeting NLRP3 inflammasome may be useful strategy to decrease the bone marrow injury caused by radiation via pyroptosis. Besides, it is reported that 10-Gy abdominal irradiation led to oxidative stress, inflammatory reaction, and NLRP3-mediated pyroptosis, and ultimately resulted in intestinal injury in mouse model [188]. Since flagellin A N/C could effectively inhibit radiation-induced pyroptosis, and in turn alleviating the intestinal injury, it is assumed that flagellin A N/C may be a potential candidate to protect patients against ionizing radiation damage [190].

**The adverse effects of pyroptosis on tumor therapy**

Tissue damage is undoubtedly the most common side effect of oncolgic therapies that targeting pyroptosis [49, 191]. As previous studies showed, chemo-drugs mainly induce pyroptosis by the executioner GSDME via caspase-3 activation. Therapies that targeting cancer cells with high GSDME expression are speculated to show a promising therapeutic effect. However, it is worth noting that GSDME has been widely overexpressed in normal cell while most tumor cells tend to express low GSDME due to GSDME gene promoter methylation [62, 166]. Thus, we may observe an interesting phenomenon that tumor cells with low or no expression of GSDME underwent apoptosis after chemotherapies, while normal tissues with high GSDME expression may suffer from severe toxicity via caspase-3-mediated pyroptosis. For instance, studies found that GSDME<sup>−/−</sup> mice were protected from chemotherapy-induced tissue damage and weight loss, while intraperitoneal injection of cisplatin or 5-FU caused immune cell infiltration and severe small intestinal injury in GSDME<sup>+/+</sup> mice [62, 192].

Meanwhile, the tight correlation between chemotherapy-induced tissue damage and pyroptosis also provides a promising strategy to reduce toxicity by inhibition of pyroptosis. For instance, DOX, a common antineoplastic agent, can cause cardiotoxicity via pyroptosis in clinical practice [193–195]. MCC950, an NLRP3 inflammasome inhibitor, could obviously suppress myocardial inflammation and fibrosis by inhibiting pyroptosis of cardiomyocyte in DOX-treated mice [193]. Similarly, tripartite motif containing 25 (TRIM25) with E3 ubiquitin ligase activities, could ubiquitinate NLRP1 in DOX-induced cardiomyocyte pyroptosis in vivo, thus protecting against myocardial damage [194]. These studies prompt us that co-treatment of anti-pyroptosis agents, such as MCC950 or TRIM25, may attenuate the myocardial injury induced by chemotherapies in cancer patients.

**CRS, characterized by excessive production of pro-inflammatory cytokines, is another adverse effect of pyroptosis-related therapy** [94, 196]. Studies found that immune cells like CD8<sup>+</sup>T cells and NK cells release large amount of perforin, GzmA and GzmB which can, respectively, cleave GSDMB and GSDME, thus further promoting pyroptosis and pore-forming process [95, 96]. As a result, cytokines like IL-1β, IL-18, ATP, LDH, and HMGB1 are released into the intercellular substance which subsequently activates immune cells like macrophages, dendritic cells, and NK cells, resulting in severe positive feedback regulatory between immune response and pyroptosis. Activation of pyroptosis in macrophages may release IL-1, IL-6, and TNF-α into serum, thus further exacerbating cytokine storm [197, 198]. One study confirmed CRS occurrence obviously decreased when depleting macrophages, knocking out GSDME, or inhibiting caspase-1 [94], which further affirmed the relationship between immune response and pyroptosis (Fig. 7).

**Challenges and perspectives**

Pyroptosis related therapies can undoubtedly affect tumorigenesis, metastasis, proliferation, and invasion [31, 32, 199]. To date, most pyroptosis-related studies are focused on adult malignancies, in contrast to inadequate attention to other common childhood tumors including hepatoblastoma, Wilms tumor, and germ cell tumor. But still, the pharmacological effect of pyroptosis can eliminate...
malignant tumor cells and has been emerging for treatment of cancers [77, 200]. Cytotoxic therapy is still the mainstream of pyroptosis-related treatments in pediatric malignancies, though with limited efficacy and obvious side effects [77]. Few identified tumor-specific regulatory mechanisms and inconsistent results concerning the role of pyroptosis in tumors may indicate an extra-high heterogeneity and complex microenvironment in pediatric cancers. Before implementation of pyroptosis-related therapies in clinical practice, multiple challenges remain to be addressed.

First, GSDME is hardly expressed in most tumor cells, but abundantly expressed in normal cells [62, 170, 201]. However, as previous studies showed, GSDME is the target of most chemotherapies. The distribution of GSDME may lead to poor efficacy and inevitable cytotoxicity or tissue damage. But gasdermin family proteins are still the potential biomarkers of tumor immunotherapy if we can upregulate gasdermin levels in tumor cells. Decitabine, a DNA methylation inhibitor drug which can upregulate GSDME expression in several cancers and increase their sensitivity to chemotherapy drug-induced pyroptosis, is undoubtedly a promising candidate [171, 172]. Additionally, the exploration of small molecule drugs and the study of specific targeting carriers to target pyroptosis also shed good insights for pediatric cancer treatments.

Second, scant attention has been paid to childhood malignancies in research on pyroptosis-related treatments. Despite some commonalities, pediatric cancers are fundamentally different from their adult counterparts [202]. Originated from embryonal cells, most of pediatric cancers are characterized by low mutational burden and relative lack of neoantigen expression, which wholly restrict their susceptibility to many chemical therapy drugs. This may also be the reason why there are few relevant studies regarding pyroptosis in pediatric cancers.

Third, the immune response to the therapies might also be totally different in children and adults, indicate that the results learned from the latter may not be that applicable to the former. Combination of different

---

**Fig. 7** Adverse effects of chemotherapy drugs and nonchemotherapy drugs in pyroptosis pathway. 

- **a** Tissue damage: pyroptosis triggered by chemotherapy drugs in normal cells with high GSDME-expression contributes to their cytotoxicity mainly via GSDME-mediated pyroptosis.
- **b** Cytokine storm: immune cells like CD8+ T cells and NK cells release a large amount of perforin, GzmA and GzmB, thus promoting pyroptosis and pore-forming process. Cytokines like IL-1β, IL-18, ATP, LDH, and HMGB1 are released into the intercellular substance which subsequently activate immune cells, resulting in severe positive feedback regulatory between immune response and pyroptosis. Activation of pyroptosis in macrophages can release IL-1, IL-6, and TNF-α, thus further exacerbating cytokine storm.
therapies may also mitigate the challenges. For instance, pembrolizumab and ipilimumab, the common checkpoint inhibitors, can promote the proliferation of cytotoxic T-lymphocyte via programmed cell death protein 1 (PD-1) inhibition and maintain the active state of these cells via cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibition, respectively [203–205]. The concurrent inhibition of PD-1/CTLA-4 signaling therapy has shown improved anti-tumor efficacy and acceptable safety profile in a phase I adult metastatic melanoma trial [205, 206]. Combination of different pyroptosis-related therapies may also worth exploration, but we should cautiously take the toxicity and safety of the young age into account.

Conclusions
Accumulating evidences have confirmed an important role of pyroptosis in pediatric cancers. Although it is justifiable that severe side effects and inconsistent mechanism are still challenges that need to be fully elucidated, the future interpretation of pyroptosis in pediatric cancers should be viewed with optimism. Repurposing of existing chemo-drugs, development of novel natural products, synthetic bioactive agents, and promising combination of reagents have brought numerous treatment strategies and novel insights into various pediatric malignancies. With deeper understanding of these diseases and tumor microenvironment, mounting therapies will also flourish continuously and come into development. Herein, we describe the molecular mechanisms of pyroptosis, highlight and discuss the opportunities and challenges for regulating pyroptosis pathways through multiple oncologic treatments in the following malignancies: osteosarcoma, neuroblastoma, leukemia, lymphoma, and brain tumors. It is believed that leverage the strengths of these therapies and overcome the adverse effects will hopefully help us with better understanding of pyroptosis in pediatric cancers and enable better care for the young population.

Abbreviations
ACD: Accidental cell death; ALL: Acute lymphocytic leukemia; AML: Acute myeloid leukemia; ASC: Apoptosis-related speck-like protein; ATP: Adenosine triphosphate; BAFF: B cell-activating factor; BRAFI: BRAF inhibitors; CARD8: Caspase recruitment domain-containing protein 8; CAR-T: Chimeric antigen receptor-T; cFLIP: Cellular FLICE-inhibitory protein; CNS: Central nervous system; COX10: Coenzyme Q10; CPF: Chlorpyrifos; CRS: Cytokine release syndrome; CTLA-4: Cytotoxic T-lymphocyte-associated antigen 4; CX43: Connexin 43; DAMP: Damage-associated molecular pattern; DOX: Doxorubicin; DPP: Dipeptidyl peptidases; eEF-2K: Eukaryotic elongation factor-2 kinase; ER: Endoplasmic reticulum; FADD: Fas-associated death domain; FDA: Food and Drug Administration; GBM: Glioblastoma multiforme; GG: Galangin; GSDM: Gasdermin D; GSDMB: Gasdermin B; GSDMC: Gasdermin C; GSDMD: Gasdermin D; GSDME: Gasdermin E; CD8: Gasdermin E N-termini; GSH: Glutathione; GzmA: Granzyme A; GzmB: Granzyme B; HL: Hodgkin lymphoma; HMGB1: High-mobility group protein box 1; HUVECs: Human umbilical vein endothelial cells; ICD: Immunogenic cell death; IL: Inter-leukin; iNKT: Invariant nature killer T; INK: C-Jun N-terminal kinase; LDH: Lactic dehydrogenase; LncRNA: Long noncoding RNA; LPS: Lipopolysaccharide; MDS: Myelodysplastic syndromes; Meki: MEK inhibitors; MM: Mixed lineage kinase domain-like; MOAP: Mitochondrial outer membrane permeabilization; NADPH: Nicotinamide adenine dinucleotide phosphate; NFκB: Nuclear factor κB; NHL: Non-Hodgkin lymphoma; NK: Natural killer cells; NLRCA4: NLR family CARD domain-containing protein 4; NLRP3: Nod-like receptor protein 3; NLRs: Nod-like receptors; OGD: Oxygen–glucose deprivation; PAMPs: Pathogen-associated molecular patterns; PCD: Programmed cell death; PD-1: Programmed cell death protein 1; PD-L1: Programmed cell death ligand 1; pHGG: Pediatric high-grade gliomas; PRRs: Pattern recognition receptors; PTX: Paclitaxel; rAAV: Recombinant adeno-associated virus; RIP: Receptor-interacting protein; RIPK: Receptor-interacting serine/threonine kinase; ROS: Reactive oxygen species; tBid: Truncated Bid; TCD: Tolerogenic cell death; TFBIP: 2-(4-′(Trifluoromethyl)-[1,1′-Biphenyl]-4-yl)-1H-imidazo[4,5-f]-[1,10]phenanthroline; TLRs: Toll-like receptors; TMBZ: Temozolomide; TNF: Tumor necrosis factor; TRIM25: Tripartite motif containing 25.

Acknowledgements
Not applicable.

Author contributions
CT conceived and designed the work. HW, XWZ, CBL, SXY, CYF, and JYH collected and analyzed the relevant reports. HW wrote the paper. CT and ZHL provided substantial contributions to improve the content of the article. All authors have read and approved the manuscript.

Funding
This work was supported by the National Natural Foundation of China (82272664, 81902745), Hunan Provincial Natural Science Foundation of China (2022JJ30843), the Science and Technology Development Fund Guided by Central Government (2021Szvup169), and Hunan Provincial Administration of Traditional Chinese Medicine Project (No. D2022117).

Availability of data and materials
The data used to support this study are included within the article.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
All authors have agreed on the contents of the manuscript.

Competing interests
The authors declare no conflict of interest.

Author details
1 Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China. 2 Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China. 3 Xiangya School of Medicine, Central South University, Changsha 410011, Hunan, China. 4 Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.

Received: 7 August 2022 Accepted: 4 October 2022
Published online: 08 October 2022

References
1. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinisi P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541.
2. Zebelli SG, Dong X. Cell-cycle regulators and cell death in immunity. Cell Host Microbe. 2013;18(4):402–7.
3. Deter RL, Baudhuin P, De Duve C. Participation of lysosomes in cellular autophagy induced in rat liver by glucagon. J Cell Biol. 1967;35(2):C11–6.

4. Deter RL, De Duve C. Influence of glucagon on the cellular autophagy on some physical properties of rat liver lysosomes. J Cell Biol. 1967;33(2):437–49.

5. Liu X, Xia S, Zhang Z, Wu H, Lieberman J. Channelling inflammation: gasdermins in physiology and disease. Nat Rev Drug Discov. 2021;20(5):384–405.

6. Friedlander AM. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem. 1986;261(16):7123–6.

7. Zheng M, Kanneganti TD. The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PA/NPoptosis). Immunol Rev. 2020;297(1):26–38.

8. Malireddi RKS, Kesanvathana S, Kanneganti TD. ZBP1 and TAK1: master regulators of NLRP3 inflammasome/pyroptosis, apoptosis, and necroptosis (PAN-optosis). Front Cell Infect Microbiol. 2019;4:406.

9. Hölter N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1(6):489–95.

10. Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26(3):165–76.

11. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72.

12. Kahlsion MA, Dixon SJ. Copper-induced cell death. Science. 2022;375(6586):1231–2.

13. Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022;32(5):417–8.

14. David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci (Landmark Ed). 2009;14(3):1116–28.

15. Delettre C, Yuste VJ, Moubarak RS, Bras M, Lesbordes-Brion JC, Petres et al. Fas-induced and crosstalk. Cell Death Differ. 2019;26(1):99–114.

16. Song X, Zhu S, Xie Y, Liu J, Sun L, Zeng D, et al. JTC801 induces pH-dependent apoptosis in pancreatic cancer cells. Sci Rep. 2022;12(1):809806.

17. Gao Y, Volegova M, Nasholm N, Das S, Kostiakowsky N, Abraham BJ, et al. Recent advances in the molecular mechanisms underlying pyroptosis in sepsis. Mediat Inflamm. 2021;2021:12:870780.

18. Zeng M, Karki R, Kancharana B, Berns H, Pruetz-Miller SM, Kanneganti TD. Caspase-6 promotes activation of the caspase-11-NLRP3 inflammasome during gram-negative bacterial infections. J Biol Chem. 2021;297(6):101379.

19. Eisfeld HS, Simonis A, Winter S, Chhen J, Stroh LJ, Krey T, et al. Viral glycoproteins induce NLRP3 inflammasome activation and pyroptosis in macrophages. Viruses. 2021;13(1):110.

20. Kijima M, Mizuta R. Histone H1 quantity determines the efficiencies of apoptosis, arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo. J Cell Physiol. 2020;235(3):2911–24.

21. Liu X, Liu J, Ding R, Li Z. Prognostic value of a pyroptosis-related long noncoding RNA signature associated with osteosarcoma microenvironment. J Oncol. 2021;2021:2128761.

22. Zhao MW, Yang P, Zhao LL. Chlorpyrifos activates cell pyroptosis and increases susceptibility to oxidative stress-induced toxicity by mir-181/SIRT1/PGC-1α/Nrf2 signaling pathway in human neuroblastoma SH-SY5Y cells. Mediat Inflamm. 2019;2019(6):699–707.

23. Tang D, Yang Z, Chen L, Wang X, Gu S, Wang J, et al. Novel pyroptosis-related signature for predicting prognosis and indicating immune microenvironment features in osteosarcoma. Front Genet. 2021;12:780780.

24. Yang Z, Chen Y, He R, Le X, Mao L, Jiang P, Ni C, et al. Exosomes derived from hypoxic bone marrow mesenchymal stem cells rescue OGD-induced injury in neural cells by suppressing NLRP3 inflammasome-mediated pyroptosis. Exp Cell Res. 2021;462(1):112635.

25. Zheng J, Chen Y, He Q. Distinct characteristics of dasatinib-induced pyroptosis in gaseidermin E-expressing human lung cancer A549 cells and neuroblastoma SH-SY5Y cells. Oncol Lett. 2020;20(1):145–54.

26. Zhao MW, Yang P, Zhao LL. Chlorpyrifos activates cell pyroptosis and increases susceptibility to oxidative stress-induced toxicity by mir-181/SIRT1/PGC-1α/Nrf2 signaling pathway in human neuroblastoma SH-SY5Y cells: Implication for association between chlorpyrifos and Parkinson’s disease. Environ Toxicol. 2019;34(6):699–707.

27. Tang D, Yang Z, Chen L, Wang J, Li X, Hua J, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13(1):110.

28. Cerella C, Teiten MH, Radogna F, Dicato M, Diederich M. From nature to bedside: pro-survival and cell death mechanisms as therapeutic targets in cancer treatment. Pediatr Blood Cancer. 2019;66(8):e27809.

29. Cerella C, Teiten MH, Radogna F, Dicato M, Diederich M. From nature to bedside: pro-survival and cell death mechanisms as therapeutic targets in cancer treatment. Pediatr Blood Cancer. 2019;66(8):e27809.

30. Ren LW, Li W, Zheng XJ, Liu JY, Yang YH, Li S, et al. Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arressing cell cycle. Acta Pharmacol Sinica. 2021. https://doi.org/10.1038/s41401-022-00971-x.

31. Thi HT, Hong S. Inflammasome as a therapeutic target for cancer prevention and treatment. J Cancer Prev. 2017;22(2):62–73.

32. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev. 2010;29(2):243–8.

33. Ding Q, Zhang W, Cheng C, Mo F, Chen L, Peng G, et al. Diclofenac inhibits the growth of human osteosarcoma by inducing G2/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo. J Cell Physiol. 2020;235(3):2911–24.

34. Liang K, Wei H, Wang S, Huang Z, Chen H, Zhang S, et al. Gaseidermin D expression and clinicopathologic outcome in primary osteosarcoma patients. Int J Clin Exp Pathol. 2020;13(12):3149–57.
48. Walker PR, Leblanc J, Smith B, Pandey S, Sikorska M. Detection of DNA fragmentation and endonucleases in apoptosis. Methods. 1999;17(4):329–38.

49. Chen X, Zeh HJ, Kang R, Kroemer G, Tang D. Cell death in pancreatic cancer: from pathogenesis to therapy. Nat Rev Gastroenterol Hepatol. 2021;18(11):804–23.

50. Wang Y, Peng J, Xie X, Zhang Z, Li M, Yang M. Gadermin E-mediated programmed cell death: an unpaired path to tumor suppression. J Cancer. 2021;12(17):5241–8.

51. Tonnis W, Bellavigna A, Beuschlein F, Eisenhofer G, Fassnacht M, Kroiss M, et al. The role of regulated necrosis in endothelial diseases. Nat Rev Endocrinol. 2021;17(8):497–510.

52. Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, et al. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18(1):100.

53. Wang Y, Kanneganti TD. From pyroptosis, apoptosis and necroptosis to PAPOsition: a mechanistic compendium of programmed cell death pathways. Comput Struct Biotechnol J. 2021;19:19641–57.

54. Jiang W, Deng Z, Dai X, Zhao W. PAPOsition: a new insight into oral infectious diseases. Front Immunol. 2021;12:789610.

55. Jiang M, Qi L, Li W, Wu Y, Song D, Li Y. Caspase-8: a key protein of cross-talk signal way in “PAPOsition” in cancer. Int J Cancer. 2021;149(7):1408–20.

56. Qiu Y, Cao Y, Cao W, Ja Y, Lu N. The application of ferroptosis in diseases. Pharmacol Res. 2020;159:104919.

57. Mao C, Liu X, Zhang Y, Zeng Z, Lei G, Yan Y, Lee H, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593(7860):586–90.

58. Ulbgavier M, Tachdjan A, Ramesh V, Chen B, Mitchell EC, Martin-Sandoval MS, et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature. 2020;585(7623):113–8.

59. Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle complexes entrapped in liposomes trigger mitochondria-mediated ferroptosis defence. Biochem. 2021;59(3766):1022–36.

60. Lin L, Zhang MX, Zhang L, Zhang D, Li C, Li YL. Autophagy, pyroptosis, and ferroptosis: new regulatory mechanisms for atherosclerosis. Front Cell Dev Biol. 2019;8:809955.

61. D’Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43(6):582–92.

62. Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99–103.

63. Ball B, Zedan A, Gore SD, Prebet T. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Leuk Lymphoma. 2017;58(5):1022–36.

64. Zhang CC, Li CG, Wang YF, Xu LH, He XH, Zeng QZ, et al. Chemo-sensitive receptor regulates NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183(2):787–91.

65. Xing Y, Yao X, Li H, Xue G, Guo Q, Yang G, et al. Cutting edge: TRAF6 mediates TLR/IL-1R signaling-induced nontranscriptional priming of the NLRP3 inflammasome. J Immunol. 2017;199(5):1561–6.

66. Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6(1):128.

67. He Y, Aker O. Microbial modulation of host apoptosis and pyroptosis. Front Cell Infect Microbiol. 2014;4:83.

68. Liston A, Masters SL. Homeostasis-altering molecular processes as mechanisms of inflammasome activation. Nat Rev Immunol. 2017;17(3):208–14.

69. Jing W, Lo Pilato J, Kay C, Man SM. Activation mechanisms of inflammasomes by bacterial toxins. Cell Microbiol. 2021;23(4):e13039.

70. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert DV. LPS recognition by both caspase-4 and caspase-5. Eur J Immunol. 2015;45(10):2918–26.

71. Schmid-Burgk JL, Gaidt MM, Sharma S, Bogoy M, Robertson SA, Rock KL. Multiple cathepsins promote pro-IL-1β synthesis and NLRP3-mediated IL-1β activation. J Immunol. 2015;195(4):1685–97.

72. Samways DS, Li Z, Egan TM. Principles and properties of ion flow in P2X receptors. Front Cell Neurosci. 2014;8:6.

73. Lee GS, Subramanian N, Kim AI, Aksentijevich I, Goldbach-Mansky R, Sacks DB, et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and CAMP. Nature. 2012;492(7427):123–7.

74. Schimid-Burgk JL, Gaidt MM, Schmid T, Ebert TS, Beckwith KS, Beckwith MS, Sætra RS, Kim H, Marstad A, et al. Plasma membrane damage causes NLRP3 activation and pyroptosis during Mycobacterium tuberculosis infection. Nat Commun. 2021;12(1):2270.

75. Baker PJ, Boucher D, Bierschenk D, Tschopp J, Whitney P, D’Silva DB, et al. NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5. Eur J Immunol. 2015;45(10):2918–26.

76. Ruhl S, Broz P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux. Eur J Immunol. 2015;45(10):2927–36.

77. Orloowski GM, Colbert JD, Sharma S, Bogoy M, Robertson SA, Rock KL. Multiple cathepsins promote pro-IL-1β synthesis and NLRP3-mediated IL-1β activation. J Immunol. 2015;195(4):1685–97.

78. Orning P, Weng D, Starheim K, Ratner D, Best Z, Lee B, et al. Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death. Science. 2018;362(6418):1064–9.

79. Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu J, et al. PD-L1-mediated gasdermin E expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020;22(10):1264–75.

80. Blasco MT, Gomis RR. PD-L1 controls cancer pyroptosis. Nat Cell Biol. 2020;22(10):1157–9.

81. Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020. https://doi.org/10.1126/sciimmunol.aaaz969.

82. Zhang Z, Zhang Y, Xia S, Kong Q, Liu X, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579(7799):415–20.
96. Zhou Z, He H, Wang K, Shi X, Wang Y, Su Y, et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. 2020. https://doi.org/10.1126/science.aaz3548.

97. Wang J, Liu S, Shi J, Li J, Wang S, Liu H, et al. The role of miRNA in the diagnosis, prognosis, and treatment of osteosarcoma. Cancer Biol Radiopharm. 2019;34(4):105–13.

98. Tu C, Yang K, Wan L, He J, Qi L, Wang W, et al. The crosstalk between IncRNAs and the Hippo signalling pathway in cancer progression. Cell Prolif. 2020;53(9): e12887.

99. Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722–35.

100. Zhang W, Liu Z, Yang Z, Feng C, Zhou X, Tu C, et al. MTHFR polymorphism is associated with severe methotrexate-induced toxicity in osteosarcoma treatment. Front Oncol. 2021;11:781386.

101. Bai L, Wang S. Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med. 2014;65:139–55.

102. Zhang C, He J, Qi L, Wang L, Wang W, Tu C, et al. Diagnostic and prognostic significance of dysregulated expression of circular RNAs in osteosarcoma. Expert Rev Mol Diagn. 2021;21(2):235–44.

103. Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. Sicot J. 2018;4:12.

104. Zhang C, He J, Qi L, Ren X, Zhang C, Duan Z, et al. Emerging landscape of lncRNAs and the Hippo signalling pathway in cancer progression. Cell Physiol. 2020;235(12):9037–58.

105. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—a collaborative pathway to success. J Clin Oncol. 2020;38(2):566–80.

106. Tu C, He J, Qi L, Ren X, Zhang C, Duan Z, et al. The potential role of DFNA5, a hearing impairment gene, in the reported management of pulmonary metastases in osteosarcoma. Cancer Med. 2015;4(4):523–31.

107. Swift CC, Eklund MJ, Kraveka JM, Alazraki AL. Updates in diagnosis, prognosis, and treatment of osteosarcoma. Cancer Biother Radiopharm. 2020;15(1):23.

108. Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview of MIBG imaging and new tracers. Sicot J. 2018;4:12.

109. Pfluger T, Piccardo A. Neuroblastoma: MIBG imaging and new tracers. Sicot J. 2018;4:12.

110. Peng J, Jiang H, Guo J, Huang J, Yuan Q, Xie J, et al. The 2016 revision of the World Health Organization classification of hematopoietic and lymphoid neoplasms. Blood. 2016;127(20):2375–90.

111. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 2003;22(47):7485–95.

112. Chen L, Weng B, Li H, Wang H, Li Q, Wei X, et al. A thiophorin derivative with low murine toxicity with therapeutic potential on lung cancer acting through a NF-κB mediated apoptosis-to-pyroptosis switch. Apoptosis. 2019;24(1–2):74–82.

113. Feng J, Li M, Wei Q, Li S, Song S, Hua Z. Unconjugated bilirubin induces pyroptosis in cultured rat cortical astrocytes. J Neuroinflammation. 2018;15(1):23.

114. Guo J, Liu S, Shi J, Li J, Wang S, Liu H, et al. The role of miRNA in the diagnosis, prognosis, and treatment of osteosarcoma. Cancer Biol Radiopharm. 2019;34(4):105–13.

115. An Q, Fan CH, Xu SM. Recent perspectives of pediatric leukemia: an update. Eur Rev Med Pharmacol Sci. 2017;21(4 Suppl):31–6.

116. Gonzalez-Herrero I, Rodríguez-Hernández G, Luengas-Martínez A, Isidro-Hernández M, Jiménez R, García-Cenador MB, et al. The making of leukemia. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19051494.

117. Metayer C, Milne E, Clavel J, Infante-Rivard C, Petridou E, Taylor M, et al. The childhood leukemia international consortium. Cancer Epidemiol. 2013;37(3):336–47.

118. Amitay EL, Keinan-Boker L. Breastfeeding and childhood leukemia incidence: a meta-analysis and systematic review. JAMA Pediatr. 2015;169(6):e151025.

119. Razmara M, Srivastava SM, Wang L, Poyet JL, Geddes BJ, DiStefano PS, et al. CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis. J Biol Chem. 2002;277(16):13952–8.

120. Johnson DC, Taabazuing CY, Okono MC, Chiu AJ, Rao SD, Brown FC, et al. DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukaemia. Nat Med. 2018;24(8):1151–6.

121. Linder A, Bauernfried S, Cheng Y, Albanease M, Jung C, Keptter OT, et al. CARD8 inflammasome activation regulates pyroptosis in human T cells. Embo J. 2020;39(19):e105071.

122. Okono MC, Johnson DC, Sindhuran R, Go EB, Chiu AJ, Wang MS, et al. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat Chem Biol. 2017;13(1):46–53.

123. Murakami T, Ockinger J, Yu J, Byles V, McColl A, Hofer AM, et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc Natl Acad Sci U S A. 2012;109(28):11282–7.

124. Horng T. Calcium signaling and mitochondrial destabilization in the triggering of the NLRP3 inflammasome. Trends Immunol. 2014;35(6):253–61.

125. Suzuki-Kakisaka H, Sugimoto J, Tetarbe M, Romani AM, Ramirez Kitchen CM, Bernstein HB. Magnesium sulfate increases intracellular magnesium reducing inflammatory cytokine release in neonates. Am J Reprod Immunol. 2013;70(3):213–20.

126. Schröder NW, Eckert J, Stubbs G, Schumann RR. Immune responses induced by sialic acid containing pirocternal outer membrane lipoproteins and glycolipids. Immunology. 2008;123(3–4):329–40.

127. Liao X, Zhang X, Lan G, Cao Z, Zhao T, Zeng T, et al. The outer membrane protein Tcp92 of treponema pallidum induces human mononuclear cell death and IL-8 secretion. J Cell Mol Med. 2018;22(12):6039–54.

128. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. CAR T-cell therapy for large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.

129. Sadelanai M, Rivière I, Riddell S. Therapeutic T-Cell engineering. Nature. 2017;545(7655):423–31.

130. Wang C, Liu J, Liu Y. Progress in the treatment of HIV-associated lymphoma when combined with the antiretroviral therapies. Front Oncol. 2021;11:798008.

131. Allen CE, Kelly KM, Rolland CM. Pediatric lymphomas and histiocytic disorders of childhood. Pediatr Clin North Am. 2015;62(1):139–65.

132. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch M, et al. Sesamin attenuates lipopolysaccharide-induced acute lung injury by inhibition of TLR4 signaling pathways. Inflammation. 2016;39(1):467–72.

133. Xu P, Cai F, Liu X, Guo L. Sesamin inhibits lipopolysaccharide-induced proliferation and invasion through the p38-MAPK and NF-κB signaling pathways in prostate cancer cells. Oncol Rep. 2015;33(6):3117–23.
144. Meng Z, Liu H, Zhang J, Zheng Z, Wang Z, Zhang L, et al. Sesamin promotes apoptosis and pyroptosis via autophagy to enhance antitumour effects on murine T-cell lymphoma. J Pharmacol Sci. 2021;147(3):260–70.
145. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491–502.
146. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol. 2000;12(1):85–98.
147. Lim KH, Chen LC, Hsu K, Chang CC, Chang KY, Kao CW, et al. BAFF-driven NLPR inflammasome activation in B cells. Cell Death Dis. 2020;11(9):820.
148. Lan P, Fan Y, Zhao Y, Lou X, Monsour HP, Zhang X, et al. TNF superfamily receptor OX40 triggers invariant NK cell pyroptosis and liver injury. J Clin Invest. 2017;127(6):2222–34.
149. Udaka YT, Packer RJ. Pediatric brain tumors. Neurol Clin. 2021;39(1):1–19.
150. Jones C, Karajannis MA, Jones DTW, Kieran MW, Monje M, Baker SJ, et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol. 2017;19(2):153–61.
151. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–50.
152. Booth TC, Wiegens EC, Warnert EA, Schmaineda KM, Riemer F, Nechifor RE. High-grade glioma treatment response monitoring biomarkers: a position statement on the evidence supporting the use of advanced MRI techniques in the clinic, and the latest bench-to-bedside developments. Part 2: spectroscopy, chemical exchange saturation, multiparametric imaging, and radiomics. Front Oncol. 2021;11:811425.
153. Perry JR, Lapierriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027–37.
154. Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for the treatment of glioblastoma. N Engl J Med. 2017;376(1):1027–37.
155. Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2014;133(1):25–36.
156. Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. Bantam family small-molecule drugs to improve cancer therapy: current situation and future directions. Acta Pharm Sin B. 2020;12(4):e1240.
157. Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells. Apoptosis. 2014;19(1):241–58.
158. Herrera FG, Irving M, Kandalaft LE, Coukos G. Rational combinations of immunotherapy with radiotherapy in ovarian cancer. Lancet Oncol. 2019;20(8):e417–33.
159. Ko EC, Raben D, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunomodulation and anti-tumor abscopal effect combining immune checkpoint blockade. Cancers (Basel). 2020;12(1):70.
160. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology. 2014;3: e285189.
161. Vasudevan VN, Yom SS. Combining systemic therapy with radiation: head and neck cancer treatments in an era of targeted agents and immunotherapy. J Natl Compr Canc Netw. 2020;18(7):907–13.
162. Herrera FG, Irving M, Kandalaft LE, Coukos G. Rational combinations of immunotherapy with radiotherapy in ovarian cancer. Lancet Oncol. 2019;20(8):e417–33.
163. Kim MS, Chang X, Yamashita K, Nagpal JK, Baek JH, Wu G, et al. Aberrant promoter methylation and tumor suppressive activity of the DFNAS gene in colorectal cancer. Oncogene. 2008;27(25):3624–34.
164. Yokomizo K, Harada Y, Kijima K, Shinmura K, Sakata M, Sakuraba K, et al. Methylation of the DFNAS gene is frequently detected in colorectal cancer. Anticancer Res. 2012;32(4):1319–22.
165. Wang CJ, Tang L, Shen DW, Wang C, Yuan QY, Gao W, et al. The expression and regulation of DFNAS in human hepatocellular carcinoma DFNAS in hepatocellular carcinoma. Mol Biol Rep. 2013;40(12):6525–31.
166. Akino K, Toyota M, Suzuki H, Imai T, Murayama R, Kusano M, et al. Identification of DFNAS as a target of epigenetic inactivation in gastric cancer. Sci Cancer. 2007;98(1):88–95.
167. Diesch J, Le Pannier MM, Winkler R, Casqueso R, Muhar M, van der Garde M, et al. Inhibition of CBP synergizes with the RNA-dependent mechanisms of azacitidine by limiting protein synthesis. Nat Commun. 2021;12:7060.
168. Ma J, Ge Z. Comparison between dicabpine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis. Front Pharmacol. 2021;12:701690.
169. Schauder DM, Kim J, Nihjawan RL. Evaluation of the use of capcetibine for the treatment and prevention of actinic keratoses, squamous cell carcinoma, and basal cell carcinoma: a systematic review. JAMA Dermatol. 2020;156(10):1117–24.
170. Li M, Tang D, Yang T, Qian D, Xu R. Apoptosis triggering, an important way for natural products from herbal medicines to treat pancreatic cancers. Front Pharmacol. 2021;12:796300.
171. Tilaou M, Ait Mouse H, Zayed A. Update and New Insights on Future Cancer Drug Candidates From Plant-Based Alkaloids. Front Pharmacol. 2021;12:719694.
172. Kosakovskaya-Cholody T, Lin J, Srideshikan SM, Scheffer L, Tarasova NI, Acharya JH. DKK4 downregulates GRP78/BiP expression in cancer cells. Cell Death Dis. 2017;8(12):e31246.
173. Chafouleas JG, Pardue RL, Brinkley BR, Dedman JR, Means AR. Regulation of intracellular levels of calmodulin and tubulin in normal and transformed cells. Proc Natl Acad Sci U S A. 1981;78(2):996–1000.
174. Alshour A, Abdel-Aziz AA, Mansour AM, Alpay SN, Hui L, Ozpolat B. Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells. Apoptosis. 2014;19(1):241–58.
175. Molina-Cespo A, Cadete A, Sarrio D, Gámez-Chacón M, Martínez L, Chao K, et al. Intracellular delivery of an antibody targeting gadermin-B reduces HER2 breast cancer aggressiveness. Clin Cancer Res. 2019;25(15):4946–58.
176. Cho Y, Lee S, Chang Y, Song W, Lee J, Jiang L, et al. The expression of DFNAS as a target of epigenetic inactivation in gastric cancer. Oncogene. 2007;26(1):107–17.
177. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
178. Lee SY, Ju MK, Jeon HM, Jeong TK, Lee YI, Kim CH, et al. Regulation of tumor progression by programmed necrosis. Oxd Med Cell Longev. 2018;2018:353741.
179. Chen X, Kang R, Kromeer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280–96.
180. Fu L, Lin W, Zhang J, Zhu L, Li X, Zhen T, et al. Repurposing non-oncology small-molecule drugs to improve cancer therapy: current situation and future directions. Acta Pharm Sin B. 2021;12(2):532–57.
181. Versteijne E, de Hingh I, Homs MYV, Intven MPW, Klaasse JM, van Santvoort HC, et al. Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer: Chemotherapy or chemoradiotherapy? Front Oncol. 2021;11:744161.
182. Rogers C, Fernandez-Almenini T, Mayes L, Almenini D, Cingolani G, Almenini ES. Cleavage of DFNAS by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. Nat Commun. 2017;8:14128.
189. Liu YG, Chen JK, Zhang ZT, Ma XJ, Chen YC, Du XM, et al. NLRP3 inflammasome activation mediates radiation-induced pyroptosis in bone marrow-derived macrophages. Cell Death Dis. 2017;8(2): e2579.

190. Liu T, Wu DM, Zhang F, Zhang T, He M, Zhao YY, et al. miR-142a-3p enhances FlaA N/C protection against radiation-mediated intestinal injury by modulating the IRAK1/NF-kappaB signaling pathway. Int J Radiat Oncol Biol Phys. 2022;112(5):1256–68.

191. Xiao Y, Zhang T, Ma X, Yang QC, Yang LL, Yang SC, et al. Microenvironment-responsive prodrug-induced pyroptosis boosts cancer immunotherapy. Adv Sci (Weinh). 2021;8(24): e2101840.

192. Yu X, He S. GSDME as an executioner of chemotherapy-induced cell death. Sci China Life Sci. 2017;60(11):1291–4.

193. Zhang L, Jiang YH, Fan C, Zhang Q, Jiang YH, Li Y, et al. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis. Biomed Pharmacother. 2021;143: 112133.

194. Wang X, Lian Z, Ge Y, Yu D, Li S, Tan K. TRIM25 rescues against doxorubicin-induced pyroptosis through promoting NLRP1 ubiquitination. Cardiovasc Toxicol. 2021;21(10):859–68.

195. Zhang JM, Yu RQ, Wu FZ, Qiao L, Wu XF, Fu YJ, et al. BMP-2 alleviates heart failure with type 2 diabetes mellitus and doxorubicin-induced AC16 cell injury by inhibiting NLRP3 inflammasome-mediated pyroptosis. Exp Ther Med. 2022;22(2):897.

196. Zhang J, Wu H, Yao X, Zhang D, Zhou Y, Fu B, et al. Pyroptotic macrophages stimulate the SARS-CoV-2-associated cytokine storm. Cell Mol Immunol. 2021;18(5):1305–7.

197. Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579(7799):421–6.

198. Zhang Z, Zhang Y, Lieberman J. Lighting a fire: can we harness pyroptosis to ignite antitumor immunity? Cancer Immunol Res. 2021;9(1):2–7.

199. Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother. 2020;121: 109595.

200. Tan Y, Chen Q, Li X, Zeng Z, Xiong W, Li G, et al. Pyroptosis: a new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res. 2021;40(1):153.

201. Van Laer L, Huizing EH, Verstreken M, van Zuijlen D, Wauters JG, Bossuyt PJ, et al. Nonsyndromic hearing impairment is associated with a mutation in DFNAS. Nat Genet. 1998;20(2):194–7.

202. Meyran D, Terry RL, Zhu JJ, Haber M, Ziegler DS, Eket P, et al. Early-phenotype CAR-T cells for the treatment of pediatric cancers. Ann Oncol. 2021;32(11):1366–80.

203. Cacciotti C, Choi J, Alexandrescu S, Zimmerman MA, Cooney TM, Chordas C, et al. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol. 2020;149(1):113–22.

204. Marjańska A, Drogosiewicz M, Dembowska-Bagińska B, Paweńska-Wiążkowska K, Balwierz W, Bobeff K, et al. Nivolumab for the treatment of advanced pediatric malignancies. Anticancer Res. 2020;40(12):7095–100.

205. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rzvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(12):122–33.

206. Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy. 2016;8(7):821–37.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.